Recent developments regarding multiple myeloma highlight advances in treatment access in several countries. [Brazil] Tocantins has incorporated the drug daratumumab, while [Portugal] the SNS is now funding new therapeutic combinations. In [USA], the FDA approved new drugs and the European Commission expanded the coverage of Melflufen.
Made by MielomaAI On November 17, 2026, at 12:14, based on recent news. May contain errors. View news →
In the last 3 months. On the site you’ll find the news from the last 3 months. The older ones only have the title and a link, in file by topicsIt’s a support website for people with multiple myeloma. It aims to keep things simple and clear. MielomaAI As you may find.
Collected from Portuguese newspapers, Google News (PT, EN, ES, FR) and associations and scientific societies. They are on the website 197 news: only from the last 3 months. The older ones are only shown with the title and link, in file by topicsAnd research and the MielomaAI You continue to find them. Always consult the original news article and speak with your doctor before drawing conclusions about your case. Last update: November 17, 2026, 3:21 PM.
Monday, 16/11
Tocantins incorporates high-cost medication into the treatment of multiple myeloma.Surgiu (Brazil) · 16:18 Access and public healthBrazilPT
The Tocantins State Government is expanding oncological treatment by incorporating a high-cost medication.Agência Tocantins (Brazil) · 14:27 Access and public healthBrazilPTThe first administration of daratumumab was performed on a patient with multiple myeloma attended at the HGP.
Saturday, November 14
Luciano Costa Shares His Top 10 Multiple Myeloma Abstracts at ASH 2026Oncodaily (EUA) · 18:15 Acesso e saúde públicaEUALuciano Costa Shares His Top 10 Multiple Myeloma Abstracts at ASH 2026 / American Society of Hematology (ASH), ASH 2026, cancer care, Cancer research,
Friday, November 13
REMS Certification and Team-Wide Training for Bispecific Administration in Multiple MyelomaCancerNetwork (EUA) · 15:05 Acesso e saúde públicaEUARalph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
Optimal Cytoreduction and Early Trial Referral in High-Risk Newly Diagnosed MyelomaCancerNetwork (EUA) · 13:08 Acesso e saúde públicaEUASaad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.
Thursday, November 12th
Lymphoma, Myeloma & Prostate CancerCure Today (EUA) · 15:00 Acesso e saúde públicaEUAFDA approves Mozobil for non-Hodgkin lymphoma and myeloma, and Degarelix for advanced prostate cancer.
- FDA Approval of Iberdomide Marks Historic Milestone in Multiple MyelomaCleveland Clinic (EUA) · 06:25 Acesso e saúde públicaEUA
Cobertura jornalística abrangente e atualizada, reunida a partir de fontes em todo o mundo pelo Google News.
Wednesday, 11/11
New paradigm in the treatment of multiple myeloma: combinations secure funding in Portugal in line with European recommendations.My Hematologia (Portugal) · 16:26 Access and public healthPortugalPTIn October 2026, the National Health Service (SNS) began to fund (1) new combined therapeutic options for the treatment of multiple myeloma (MM) in adult patients, indicated for the first and second lines of intervention. This approval represents a milestone in access to innovation in Haematology oncology…
Tuesday, November 10
European Commission Expands Melflufen Label to Third-Line Multiple MyelomaCancerNetwork (EUA) · 17:38 Acesso e saúde públicaEUAData from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
Monday, November 9th
European Commission Expands Melphalan Flufenamide Approval to Third-Line Treatment for Multiple MyelomaOncodaily · 12:52 Acesso e saúde públicaEuropean Commission Expands Melphalan Flufenamide Approval to Third-Line Treatment for Multiple Myeloma / dexamethasone, Drug Approval, EMA, European
Myeloma fund launches with £15m initial backingPharmaTimes (Reino Unido) · 10:44 Acesso e saúde públicaReino UnidoPhilanthropy initiative targets treatment innovation
Friday, November 6th
The Kidney in Plasma Cell Disorders: The Urgency of Early Intervention and New Therapeutic FrontiersMy Hematologia — pesquisa "mieloma" (Portugal) · 15:54 Access and public healthPortugalPTIn the session dedicated to the topic “The Kidney in Plasma Cell Disorders: Between Disease and Treatment,” Natacha Rodrigues from the ULS Santa Maria highlighted the critical importance of continuous coordination between Haematology-Oncology and Nephrology. The expert emphasized that renal involvement in these pathologies requires rigorous screening…
Wednesday, 11/04
Myeloma's Gray Zones: Sequencing, Oral Therapy, and FrailtyOncology Nursing News (EUA) · 08:00 Acesso e saúde públicaEUAAt the 2026 National Summit on Hematologic Cancers, Kate Kennedy, MSN, APRN, flagged decisions where guidelines give nurses and APPs little direction.
Tuesday, November 3rd
Mapping Practical Steps to Expand CAR T-Cell Access in Multiple MyelomaCancerNetwork (EUA) · 08:00 Acesso e saúde públicaEUAJoshua Richter, MD, and Marco Davila, MD, PhD, discuss early evaluation, sequencing, referral partnerships, and access to CAR T-cell therapy in myeloma.
Thursday, October 29th
Tecvayli monotherapy approved in EU for relapsed myeloma careRare Cancer News (Reino Unido) · 16:16 Acesso e saúde públicaReino UnidoThe EU has approved Tecvayli as a standalone injection for people whose myeloma has returned after one prior line of treatment.
